opfolda Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Opfolda, and what generic alternatives are available?
Opfolda is a drug marketed by Amicus Therap Us and is included in one NDA. There are seven patents protecting this drug.
This drug has one hundred and thirty-three patent family members in forty-one countries.
The generic ingredient in OPFOLDA is miglustat. There are two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the miglustat profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Opfolda
A generic version of opfolda was approved as miglustat by ANI PHARMS on April 17th, 2018.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for opfolda?
- What are the global sales for opfolda?
- What is Average Wholesale Price for opfolda?
Summary for opfolda
International Patents: | 133 |
US Patents: | 7 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Drug Prices: | Drug price information for opfolda |
What excipients (inactive ingredients) are in opfolda? | opfolda excipients list |
DailyMed Link: | opfolda at DailyMed |
![opfolda drug patent expirations Drug patent expirations by year for opfolda](/p/graph/s/t/opfolda-patent-expirations.png)
![Drug Prices for opfolda](/p/graph/drug-price/opfolda.png)
Pharmacology for opfolda
Drug Class | Glucosylceramide Synthase Inhibitor |
Mechanism of Action | Glucosylceramide Synthase Inhibitors |
US Patents and Regulatory Information for opfolda
opfolda is protected by seven US patents and one FDA Regulatory Exclusivity.
Patents protecting opfolda
Highly potent acid alpha-glucosidase with enhanced carbohydrates
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: THE TREATMENT OF POMPE PATIENTS
High concentration alpha-glucosidase compositions for the treatment of pompe disease
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: THE TREATMENT OF POMPE PATIENTS
Augmented acid alpha-glucosidase for the treatment of Pompe disease
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: THE TREATMENT OF POMPE PATIENTS
Highly potent acid alpha-glucosidase with enhanced carbohydrates
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: THE TREATMENT OF POMPE PATIENTS
High concentration alpha-glucosidase compositions for the treatment of Pompe disease
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: THE TREATMENT OF POMPE PATIENTS
Augmented acid alpha-glucosidase for the treatment of Pompe disease
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: THE TREATMENT OF POMPE PATIENTS
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: THE TREATMENT OF POMPE PATIENTS
FDA Regulatory Exclusivity protecting opfolda
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Amicus Therap Us | OPFOLDA | miglustat | CAPSULE;ORAL | 215211-001 | Sep 28, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Amicus Therap Us | OPFOLDA | miglustat | CAPSULE;ORAL | 215211-001 | Sep 28, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Amicus Therap Us | OPFOLDA | miglustat | CAPSULE;ORAL | 215211-001 | Sep 28, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Amicus Therap Us | OPFOLDA | miglustat | CAPSULE;ORAL | 215211-001 | Sep 28, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Amicus Therap Us | OPFOLDA | miglustat | CAPSULE;ORAL | 215211-001 | Sep 28, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Amicus Therap Us | OPFOLDA | miglustat | CAPSULE;ORAL | 215211-001 | Sep 28, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for opfolda
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Piramal Critical Care B.V. | Yargesa | miglustat | EMEA/H/C/004016 Yargesa is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease.Yargesa may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.Yargesa is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease. |
Authorised | yes | no | no | 2017-03-22 | |
Janssen Cilag International NV | Zavesca | miglustat | EMEA/H/C/000435 Zavesca is indicated for the oral treatment of adult patients with mild to moderate type-1 Gaucher disease. Zavesca may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.Zavesca is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type-C disease. |
Authorised | no | no | no | 2002-11-20 | 2009-06-16 |
Gen.Orph | Miglustat Gen.Orph | miglustat | EMEA/H/C/004366 Miglustat Gen.Orph is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease. Miglustat Gen.Orph may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.Miglustat Gen.Orph is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease. |
Authorised | yes | no | no | 2017-11-09 | |
Dipharma Arzneimittel GmbH | Miglustat Dipharma | miglustat | EMEA/H/C/004904 Miglustat Dipharma is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease.Miglustat Dipharma may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.Miglustat Dipharma is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease. |
Authorised | yes | no | no | 2019-02-18 | |
Amicus Therapeutics Europe Limited | Opfolda | miglustat | EMEA/H/C/005695 Opfolda (miglustat) is an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in adults with late-onset Pompe disease (acid α- glucosidase [GAA] deficiency). |
Authorised | no | no | no | 2023-06-26 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for opfolda
See the table below for patents covering opfolda around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 4285902 | ALPHA-GLUCOSIDASE ACIDE AMÉLIORÉE POUR LE TRAITEMENT DE LA MALADIE DE POMPE (AUGMENTED ACID ALPHA-GLUCOSIDASE FOR THE TREATMENT OF POMPE DISEASE) | ⤷ Sign Up |
Lithuania | 3201320 | ⤷ Sign Up | |
New Zealand | 729507 | Highly potent acid alpha-glucosidase with enhanced carbohydrates | ⤷ Sign Up |
South Korea | 20220146662 | 개선된 탄수화물을 가지는 고도로 강력한 산성 알파-글루코시다제 (-HIGHLY POTENT ACID ALPHA-GLUCOSIDASE WITH ENHANCED CARBOHYDRATES) | ⤷ Sign Up |
Colombia | 2017002776 | Composición de alfa glucosidasa humana recombinante y métodos para su fabricación | ⤷ Sign Up |
Japan | 2017537604 | 炭水化物が増大している非常に強力な酸性アルファ−グルコシダーゼ | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for opfolda
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3201320 | LUC00336 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: CIPAGLUCOSIDASE ALFA; AUTHORISATION NUMBER AND DATE: EU/1/22/1714 20230324 |
3201320 | 122024000016 | Germany | ⤷ Sign Up | PRODUCT NAME: CIPAGLUCOSIDASE ALFA; REGISTRATION NO/DATE: EU/1/22/1714 20230320 |
3201320 | CA 2024 00012 | Denmark | ⤷ Sign Up | PRODUCT NAME: CIPAGLUCOSIDASE ALFA; REG. NO/DATE: EU/1/22/1714 20230324 |
3201320 | 2024C/513 | Belgium | ⤷ Sign Up | PRODUCT NAME: CIPAGLUCOSIDASE ALFA; AUTHORISATION NUMBER AND DATE: EU/1/22/1714 20230324 |
3201320 | PA2024509 | Lithuania | ⤷ Sign Up | PRODUCT NAME: CIPAGLIUKOZIDAZE ALFA; REGISTRATION NO/DATE: EU/1/22/1714 20230320 |
3201320 | 301267 | Netherlands | ⤷ Sign Up | PRODUCT NAME: POMBILITI (CIPAGLUCOSIDASE ALFA); REGISTRATION NO/DATE: EU/1/22/1714 20230324 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |